País: Reino Unido
Língua: inglês
Origem: MHRA (Medicines & Healthcare Products Regulatory Agency)
Lisinopril
Lupin Healthcare (UK) Ltd
C09AA03
Lisinopril
20mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02050501; GTIN: 8901107000875
PACKAGE LEAFLET: INFORMATION FOR THE USER LISINOPRIL 2.5 MG, 5 MG, 10 MG AND 20 MG TABLETS LISINOPRIL DIHYDRATE PLEASE READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1 What Lisinopril Tablets are and what they are used for. 2 What you need to know before you take Lisinopril Tablets. 3 How to take Lisinopril Tablets. 4 Possible side effects. 5 How to store Lisinopril Tablets. 6 Contents of the pack and other information. RE USED FOR 1. WHAT LISINOPRIL TABLETS ARE AND WHAT THEY ARE USED FOR Lisinopril belongs to a group of medicines called ACE inhibitors (Angiotensin Converting Enzyme inhibitors). Lisinopril works by widening your blood vessels, which helps reduce your blood pressure and makes it easier for your heart to pump blood to all parts of your body. Your doctor has prescribed Lisinopril for one of the following reasons: • Your blood pressure is too high (hypertension). • You have a heart condition known as symptomatic heart failure, where the heart does not pump your blood around your body as well as it should. • You have had a heart attack (myocardial infarction) that may lead to a weakening of your heart. Lisinopril slows the weakening down. • You have kidney problems related to your diabetes and high blood pressure. • Lisinopril is recommended in children (above 6 years old) only for the treatment of high blood pressure (hypertension). • Lisinopril should not be used in children with severe kidney impairment. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE LISINOPRIL TABLETS DO NOT TAKE Leia o documento completo
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lisinopril 20 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 20mg: Each tablet contains 20mg of lisinopril as the dihydrate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablets 20mg: Round, pale pink coloured, uncoated, biconvex tablet with ‘20’ on one side and plain on other side Diameter: 8.00mm x 3.90mm 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS HYPERTENSION Treatment of hypertension HEART FAILURE Treatment of symptomatic heart failure ACUTE MYOCARDIAL INFARCTION Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction RENAL COMPLICATIONS OF DIABETES MELLITUS Treatment of renal disease in hypertensive patients with Type 2 diabetes mellitus and incipient nephropathy (see section 5.1) 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Lisinopril should be administered orally in a single daily dose. As with all other medication taken once daily, lisinopril should be taken at approximately the same time each day. The absorption of lisinopril tablets is not affected by food. The dose should be individualised according to patient profile and blood pressure response (see section 4.4). HYPERTENSION Lisinopril may be used as monotherapy or in combination with other classes of antihypertensive therapy (see sections 4.3, 4.4, 4.5 and 5.1). Starting dose In patients with hypertension the usual recommended starting dose is 10 mg. Patients with a strongly activated renin-angiotensin-aldosterone system (in particular, renovascular hypertension, salt and /or volume depletion, cardiac decompensation, or severe hypertension) may experience an excessive blood pressure fall following the initial dose. A starting dose of 2.5-5 mg is recommended in such patients and the initiation of treatment should take place under medical supervision. A lower starting dose is required in the presence of renal impairment (see Table 1 below). Maintenance dose The usual effective mainte Leia o documento completo